Scrip
Dendreon to raise up to $448 million to fund Provenge commercialisation
09 December 2009
Eleanor Malone
Please Login to read the full article.
09 December 2009
Eleanor Malone
Dendreon is launching a sale of its common stock in which it expects to raise about $389 million, rising to $448 million if the underwriters' over-allotment option is exercised in full. The actual amount raised will depend on the offer price, which has not yet been officially determined.
The...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Dendreon completes US filing for therapeutic cancer vaccine Provenge
- Dendreon prices public offering expecting to raise up to $410 million
- Hopes high for Provenge to become first US-approved therapeutic cancer vaccine
- Sanofi-Aventis's new chemotherapy drug Jevtana improves survival in advanced prostate cancer
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
